CFDE Data Portal | Search LINC02643

	Label	Description
	LINC02643 Gene (Entity type)	ENSG00000230109 - long intergenic non-protein coding RNA 2643
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE153867 olaparib 6 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 8 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS

LINC02643

ENSG00000230109 - long intergenic non-protein coding RNA 2643

GSE239844 crizotinib 1 v 10 human dn

A Gene Set from LINCS

GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 5 human dn

A Gene Set from LINCS

GSE153867 olaparib 6 v 4 human dn

A Gene Set from LINCS

GSE239844 crizotinib 7 v 0 human up

A Gene Set from LINCS

GSE239844 crizotinib 8 v 0 human up

A Gene Set from LINCS

GSE146982 metformin 4 v 5 human dn

A Gene Set from LINCS

GSE146982 metformin 0 v 6 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.